Presa Diretta, the broadcast reporting on the Italian hottest news, interviews Exiris CSO on pharmaceutical research and drugs costs, and on the potential spreading benefits that can raise from the... read more →
Exiris signs agreements with the Italian Institute of Health (ISS) and with Aldevron on the development of novel anticancer agents. According to two separate agreements, Exiris acquires exclusive rights to,... read more →
Exiris, in collaboration with Prof N. Sewald from the University of Bielefeld, Germany, has identified a novel class of drugs that shows picomolar activity against stem cells from colon and... read more →
Exiris signs Research Collaboration Agreement with Italfarmaco (1.4 M€).
Exiris is awarded a Marie Skłodowska-Curie European Training Network (ETN) grant in the context of the Horizon 2020 MAGICBULLET project (3.75 M€).
Exiris presents data on novel cancer stem cell targets at the EMBO Workshop: Cancer stem cells 20 years later: Achievements, controversies, emerging concepts and technologies.
Exiris is awarded a Eurotransbio grant in the context of the ColCab consortium (1.5 M€), to discover new cancer stem cell targets and specific mAbs.
Exiris signs license agreement with the Italian National Institute of Health (ISS) for the use of the ISS cancer stem cell platform.